{"entity":{"id":"nct05920135","kind":"trial","name":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","aka":[],"tldr":"A phase 1/2 trial of BBT-207 in non-small-cell lung cancer, run by Bridge Biotherapeutics, Inc., active and no longer recruiting.","summary":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI is a phase 1/2 interventional study registered as NCT05920135 by Bridge Biotherapeutics, Inc., with 24 participants enrolled, started 2023-09-11 and due to reach its primary completion in 2026-08-01. Interventions recorded: BBT-207.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05920135","url":"https://clinicaltrials.gov/study/NCT05920135"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05920135","phase":"1/2","setting":"First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI","sponsor":"Bridge Biotherapeutics, Inc.","started":"2023-09-11","startedType":"actual","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05920135/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}]}}